155 related articles for article (PubMed ID: 21251301)
1. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis B to interferon alfa.
Wang S; Huang D; Sun S; Ma W; Zhen Q
Virol J; 2011 Jan; 8():28. PubMed ID: 21251301
[TBL] [Abstract][Full Text] [Related]
2. Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection.
Yee LJ; Tang J; Gibson AW; Kimberly R; Van Leeuwen DJ; Kaslow RA
Hepatology; 2001 Mar; 33(3):708-12. PubMed ID: 11230752
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa.
Edwards-Smith CJ; Jonsson JR; Purdie DM; Bansal A; Shorthouse C; Powell EE
Hepatology; 1999 Aug; 30(2):526-30. PubMed ID: 10421663
[TBL] [Abstract][Full Text] [Related]
4. [Genetic polymorphisms of MxA protein and eIF-2a-reg2 and their responses to interferon treatment in patients with chronic hepatitis B].
Huang YX; Ma LN; Chen XY; Li Z; Huang YL; Shen CL; Ma B
Zhonghua Gan Zang Bing Za Zhi; 2007 Mar; 15(3):187-91. PubMed ID: 17407708
[TBL] [Abstract][Full Text] [Related]
5. Effects of interferon alpha therapy on the catalytic domains of the polymerase gene and basal core promoter, precore and core regions of hepatitis B virus.
Chen RY; Bowden S; Desmond PV; Dean J; Locarnini SA
J Gastroenterol Hepatol; 2003 Jun; 18(6):630-7. PubMed ID: 12753143
[TBL] [Abstract][Full Text] [Related]
6. Mutations in the X region and core promoter are rare and have little impact on response to interferon therapy for chronic hepatitis B.
Hannoun C; Horal P; Krogsgaard K; Lindh M;
J Med Virol; 2002 Feb; 66(2):171-8. PubMed ID: 11782925
[TBL] [Abstract][Full Text] [Related]
7. Association between chronic hepatitis B virus infection and interleukin-10, tumor necrosis factor-alpha gene promoter polymorphisms.
Cheong JY; Cho SW; Hwang IL; Yoon SK; Lee JH; Park CS; Lee JE; Hahm KB; Kim JH
J Gastroenterol Hepatol; 2006 Jul; 21(7):1163-9. PubMed ID: 16824070
[TBL] [Abstract][Full Text] [Related]
8. T29C genotype polymorphism of estrogen receptor alpha is associated with initial response to interferon-alpha therapy in chronic hepatitis B patients.
Zhang TT; Zhang ZH; Gao YF; Zhang YF; Yang DL; Li X
Hepatobiliary Pancreat Dis Int; 2010 Jun; 9(3):275-9. PubMed ID: 20525555
[TBL] [Abstract][Full Text] [Related]
9. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.
Buster EH; Hansen BE; Lau GK; Piratvisuth T; Zeuzem S; Steyerberg EW; Janssen HL
Gastroenterology; 2009 Dec; 137(6):2002-9. PubMed ID: 19737568
[TBL] [Abstract][Full Text] [Related]
10. Influence of interleukin-10 gene promoter polymorphisms on disease progression in patients chronically infected with hepatitis B virus.
Miyazoe S; Hamasaki K; Nakata K; Kajiya Y; Kitajima K; Nakao K; Daikoku M; Yatsuhashi H; Koga M; Yano M; Eguchi K
Am J Gastroenterol; 2002 Aug; 97(8):2086-92. PubMed ID: 12190181
[TBL] [Abstract][Full Text] [Related]
11. Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon.
Boglione L; Cusato J; Allegra S; Esposito I; Patti F; Cariti G; Di Perri G; D'Avolio A
Antiviral Res; 2014 Feb; 102():35-43. PubMed ID: 24316030
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B virus-specific T-cell proliferation and cytokine secretion in chronic hepatitis B e antibody-positive patients treated with ribavirin and interferon alpha.
Rico MA; Quiroga JA; Subirá D; Castañón S; Esteban JM; Pardo M; Carreño V
Hepatology; 2001 Jan; 33(1):295-300. PubMed ID: 11124848
[TBL] [Abstract][Full Text] [Related]
13. Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon.
Boglione L; Cusato J; De Nicolò A; Cariti G; Di Perri G; D'Avolio A
J Viral Hepat; 2015 Mar; 22(3):318-27. PubMed ID: 25060765
[TBL] [Abstract][Full Text] [Related]
14. Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China.
Sun J; Ding H; Chen G; Wang G; Wei L; Zhang J; Xie Q; Wan M; Tang H; Chen S; Gao Z; Wang Y; Zhang D; Huang W; Sheng J; Ning Q; Yang D; Lu J; Pan C; Yang Y; Wang J; Sun C; Wang Q; Hou J
BMC Gastroenterol; 2019 May; 19(1):65. PubMed ID: 31046700
[TBL] [Abstract][Full Text] [Related]
15. Genomic variations in precore and cytotoxic T lymphocyte regions in chronic hepatitis B in relationship to interferon responsiveness.
Shindo M; Okuno T
Liver; 2000 Apr; 20(2):136-42. PubMed ID: 10847482
[TBL] [Abstract][Full Text] [Related]
16. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B.
Tangkijvanich P; Komolmit P; Mahachai V; Sa-nguanmoo P; Theamboonlers A; Poovorawan Y
J Clin Virol; 2009 Oct; 46(2):117-23. PubMed ID: 19651540
[TBL] [Abstract][Full Text] [Related]
17. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D.
Erhardt A; Blondin D; Hauck K; Sagir A; Kohnle T; Heintges T; Häussinger D
Gut; 2005 Jul; 54(7):1009-13. PubMed ID: 15951551
[TBL] [Abstract][Full Text] [Related]
18. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy.
Tseng TC; Yu ML; Liu CJ; Lin CL; Huang YW; Hsu CS; Liu CH; Kuo SF; Pan CJ; Yang SS; Su CW; Chen PJ; Chen DS; Kao JH
Antivir Ther; 2011; 16(5):629-37. PubMed ID: 21817184
[TBL] [Abstract][Full Text] [Related]
19. Pegylated interferon α-2b up-regulates specific CD8+ T cells in patients with chronic hepatitis B.
Chen J; Wang Y; Wu XJ; Li J; Hou FQ; Wang GQ
World J Gastroenterol; 2010 Dec; 16(48):6145-50. PubMed ID: 21182232
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of long-term interferon therapy in chronic hepatitis B patients with HBV genotype C.
Sakai T; Shiraki K; Inoue H; Okano H; Deguchi M; Sugimoto K; Ohmori S; Murata K; Nakano T
Int J Mol Med; 2002 Aug; 10(2):201-4. PubMed ID: 12119559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
